Skip to content

Inogen INGN Operating lease liabilities

Operating lease liabilities at other companies

AdaptHealth logo
AdaptHealthAHCO
Pulmonx Corporation logo
Pulmonx CorporationLUNG

Other financials

Income statement

See full
Revenue$85.1M+3.4%
Gross profit$44.9M+1.7%
Operating income-$9.3M-21.9%
Net income-$8.3M-34.8%
EPS (diluted)-$0.30-20.0%

Balance sheet

See full
Cash & equivalents$93.1M-21.7%
Total debt$16.9M-11.9%
Total equity$182.9M-7.6%
Total assets$285.9M-7.3%

Cash flow

See full
Operating cash flow-$6.7M+60.2%
CapEx$210.0K-28.1%
Free cash flow-$6.9M+59.6%

Valuation

See full
Market cap$174.63M-9.7%
Enterprise value$98.45M-9.5%
P/S0.5×-0.1×

Profitability

See full
Gross margin52.8%-2.6pp
Operating margin-9.1%-0.8pp
Net margin-7.1%-0.8pp
FCF margin0.4%

Returns & leverage

See full
Return on equity-13.1%-0.9pp
Debt / equity0.1×0.0×
Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inogen's operating lease liabilities?
Inogen (INGN) reported operating lease liabilities of -$573K in Q1 2026.
How has Inogen's operating lease liabilities changed year-over-year?
Inogen's operating lease liabilities increased by 24.7% year-over-year, from -$761K to -$573K.
What is the long-term trend for Inogen's operating lease liabilities?
Over 3 years (2022 to 2025), Inogen's operating lease liabilities has grown at a -0.9% compound annual growth rate (CAGR), from -$3.4M to -$3.31M.